Kancera Q4: Active in 2025, FRACTIVE in 2026 - Redeye
Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, laying the foundation for the planned start of the FRACTIVE phase 2b study in 2026.
ANNONS
Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, laying the foundation for the planned start of the FRACTIVE phase 2b study in 2026.
